ETHYL p-chlorophenoxyisobutyrate (CPIB) reliably lowers Sf 20-105 concentrations and thereby lowers serum triglyceride levels, but its effect on the cholesterol-rich, triglyceride-poor Sf 0-20 class is variable and of lesser magnitude.' By contrast, thyroid-active substances lower predominantly the Sf 0-20 fraction and have a much smaller and less consistent effect on the Sf 20-105 class.2 Therefore, it appeared reasonable to study the effect of the combined administration of CPIB and levothyroxine in patients with the common type of generalized hyperlipoproteinemia characterized by moderate to marked
elevations of both Sf 0-20 and Sf 20-105 levels. In addition, observations made during prolonged administration of CPIB and thyroxine on patients with Sf 0-20 hyperlipoproteinemias are discussed.
Subjects and Methods
Thirteen ambulatory patients, aged 35 to 64 years, were studied. Table 1 lists age, sex, and diagnosis of each patient. Seven patients had had a myocardial infarction; one patient had arteriosclerotic heart disease and hypertension with definite electrocardiographic abnormalities, and the remainder had diagnoses as noted in table 1. Carbohydrate-sensitive hyperlipemia was defined as a hyperlipemia in which the concentration of the predominant triglyceride-bearing lipoprotein classes (Sf 20-105) was markedly reduced by restriction of dietary carbohydrate; one patient (case 3) had the usual associated marked impairment in carbohydrate tolerance demonstrated on repeated glucose tolerance tests. Each subject completed one or more courses of treatment with CPIB, and CPIB and thyroxine, and most were also followed while treatment with CPIB was Circulation, Volume XXXIII, February 1966 stopped but use of thyroxine continued. CPIB was given in a total daily dose of 2.0 g (0.5 g after breakfast and after lunch and 1.0 g after dinner). The dosage of levothyroxine varied from 0.2 to 0.6 mg per day. Each patient was followed personally at 4 to 8-week intervals; at each visit body weight, pulse, and blood pressure were recorded. Each patient was advised to stay on a standard low saturated fat, low cholesterol diet as follows: eggs were limited to four per week; skimmed milk, nonfat milk, or powdered milk and their products were substituted for whole milk and cream, and their products; pork products and commercially prepared cold cuts, such as salami and liverwurst, were excluded; patients were further instructed to substitute corn or safflower seed oil or both and unsaturated margarines for saturated fats, such as butter, lard, and chicken fat. Patients were also instructed to give preference, in order of decreasing desirability, to seafoods, fowl, organ meats of beef and veal (heart, lung, tripe), and lean cuts of beef, veal, and lamb.
Fruits and vegetables were allowed ad libitum, the ingestion of nuts was encouraged, and the intake of carbohydrate so regulated as to maintain constant body weight. All patients were otherwise on unrestricted diets and were repeatedly instructed to maintain their diets as constant as possible during the entire study period. On this diet the change in mean group weight was less than 1 pound.
Serum lipoprotein analyses after the differential gradient ultracentrifuge method of de Lalla and Gofman3 or by high precision refractometrv utilizing the method of Lindgren and associ-ates4 or by both, were done at 4 to 8-week intervals on all patients' serums before any drug was given, during administration of CPIB, CPIB and levothyroxine, and of thyroxine without CPIB, and during suitable control periods when no medication was given. The refractometric and analytic ultracentrifugal methods gave practically identical results for the major low density Sf 0-20 and Sf 20-105 lipoprotein classes in a large series of replicate analyses. In addition to serial lipoprotein measurements, blood cholesterol was measured, and routine complete blood counts, urinalyses, and other clinical laboratory tests were obtained as needed for the exclusion of untoward side effects of drug therapy.
The period of study varied with each individual patient but ranged from 58 to 201 weeks, and the mean observation period for the group was 104 weeks.
Results and Discussion
As has been noted before, the responses of the two major low density lipoprotein classes, Sf 0-20 and Sf 20-105, to CPIB were qualitatively and quantitatively different.' The concentration of lipoprotein in the Sf 20-105 class is lowered sharply by CPIB. This effect was found to be quite consistent in all 13 patients in the present study and did not appear to depend on the initial lipoprotein pattern. Mean lowering in the Sf 20-105 class was 55%, and the addition of levothyroxine (T-4) to the CPIB regimen did not produce any further change in concentration (table 2) .
By contrast, the Sf 0-20 response to CPIB was found to be variable, ranging from a 270% increase to a 35% decrease of the initial concentration. It became of interest to determine whether this variable Sf 0-20 response is related to the initial lipoprotein pattern. The 13 patients, therefore, were classified into one of three subgroups: (1) Sf 0-20 response to CPIB and CPIB and T-4 observed in these three subgroups with different initial lipoprotein distributions. 0-20 concentration when given CPIB. This unusual effect of CPIB is described in detail later. When T-4 was added to the CPIB regimen, a moderate but consistent Sf 0-20 reduction occurred in all seven patients (mean decrease was 11%).
In the four patients with combined Sf 0-20 and Sf 20-10(5 hyperlipoproteinemia, CPIB had no statistically significant effect on Sf 0-20 concentrations though a slight tendency for this lipoprotein class to rise was noted; the group mean Sf 0-20 rise was 5%. Addition of T-4 again resulted in a moderate but consistent Sf 0-20 decrease (mean reduction 17%, P < 0.01 ). Table 4 summarizes the lipoprotein changes observed in patient 3 with carbohydrate-sensitive hyperlipemia and early chemical diabetes mellitus with normal fasting blood sugar levels, during an observation period of 101 weeks. The large increase in Sf 0-20 concentration accompanying the expected Sf 20-105 reduction produced by CPIB is noteworthy. It is also apparent that addition of T-4 did not affect the CPIB-induced Sf 0-20 hyperlipoproteinemia significantly; nor is the slight Sf 20-105 rise noted during the CPIB and T-4 phase statistically significant. Very similar CPIB-induced changes in lipoprotein concentrations were observed in patient 2, another patient with carbohydrate-sensitive hyperlipemia (table 5). Sf 0-20 concentration increases have been noted previously in two other patients with carbohydrate-sensitive hyperlipemia and gout treated with CPIB.1 It, therefore, appears likely that the marked Sf 0-20 elevation represents a pharmacological effect of CPIB in patients vith this type of hyperlipoproteinemia.
The unusual Sf 0-20 lowering effect of CPIB in patient 7 with Sf 0-20 hyperlipoproteinemia is illustrated in figure 1 which shows lipoprotein changes induced by dextrothyroxine, a combination of 97.5% CPIB and 2.5% androsterone (Atromid), and by CPIB, CPIB and levothyroxine, and levothyroxine used separately in a healthy 45-year-old man with xanthelasma observed for more than 3 years. Figure 1 illustrates a number of interesting pharmacological effects on serum lipoprotein concentrations as follows: (1) The typical Sf 0-20 reduction produced by dextrothyroxine, followed by the usual rebound effect when use of this drug was stopped, occurred with a lesser Sf 20-105 reduction and rebound as observed in previous studies.2 5 markedly, but a trend is discernible that suggests a rebound effect due to CPIB withdrawal. Figure 2 shows a longitudinal profile of lipoprotein changes in the other patient (no. 11), with an Sf 0-20 hyperlipoproteinemia, who showed marked Sf 0-20 reduction as a result of CPIB administration. The marked Sf 20-105 reduction, even though initial concentrations were normal, is also noteworthy. In spite of the usual Sf 0-20 lowering action of thyroid-active substances, in this patient 0.4 mg daily of levothyroxine did not maintain the reduction of Sf 0-20 concentration achieved with CPIB. The expected Sf 20-106 rise on CPIB withdrawal (rebound effect) was also noted. Whether or not the estrogenic preparation (Premarin) given throughout the entire period of study had any effect on the "atypical" Sf 0-20 lowering effect of CPIB in this patient cannot be determined from our data. However, the data obtained on patient Circulation, Volume XXXIII, February 1966 7 ( fig. 1 ) demonstrate that at least in a male subject a profound CPIB-induced Sf 0-20 reduction can occur without concurrent estrogen administration. The incidence of CPIB-responsive Sf 0-20 hyperlipoproteinemias can not be determined from the data herein presented. In this author's experience only seven of 44 patients have responded to CPIB with Sf 0-20 lowering of 25% or more, an incidence of 16%. The physiological and biochemical reasons for this pharmacological effect of CPIB are unknown.
Conclusions Whereas the response of the Sf 20-105 class to CPIB is rather uniform and does not seem to depend significantly on the initial lipoprotein pattern of the patient, the Sf 0-20 response to CPIB varies greatly. Thus, in five patients with Sf 0-20 hyperlipoproteinemias, the Sf 0-20 class was not affected by CPIB, yet a substantial decrease (averaging 36 per cent) in this class occurred in two other patients. On the other hand, the Sf 0-20 concentration rose by 270% in one patient (no. 3) with carbohydrate-sensitive hyperlipemia pattern (low Sf 0-20 and high Sf 20-105 concentrations). In general, the addition of thyroid-active substances caused a decrease in Sf 0-20 levels regardless of what effect CPIB had on this lipoprotein class, but had no further effect on Sf 20-105 levels previously reduced by CPIB.
The variability of the Sf 0-20 response to CPIB is so great that meaningful interpretations cannot be based on mean group changes in lipoprotein concentrations derived from a small series of 13 patients with different initial lipoprotein patterns. Analysis of lipoprotein concentration changes induced by single and combined administration of CPIB and thyroid-active substances was made, therefore, in terms of categories of initial lipoprotein patterns.
Summary
The combined effect of CPIB and levothyroxine on lipoprotein concentrations in 13 patients with various types of hyperlipoproteinemias has been investigated. Analysis of long--term observations indicates the following: (1) CPIB lowers Sf 20-105 concentrations profoundly regardless of the initial lipoprotein distribution. (2) Addition of levothyroxine to CPIB produces no further significant effect on Sf 20-105 concentrations. (3) The effect of CPIB on Sf 0-20 concentrations appears to depend on the initial lipoprotein distribution. In carbohydrate-sensitive hyperlipemias CPIB can markedly increase Sf 0-20 levels, whereas it has no such effect in other hyperlipoproteinemias. On occasion, a marked Sf 0-20 lowering effect occurs in patients with Sf 0-20 hyperlipoproteinemias. Two such instances are reported in detail. (4) In combined Sf 0-20 and Sf 20-105 hyperlipoproteinemias the combination of CPIB and thyroxine is often more effective than either agent used separately in reducing total lipoprotein concentrations.
